MacroPAC-A® is a cranberry extract that is produced through the proprietary technology of Biosfered S.r.l.
MacroPAC-A® is first titrated with the BL-DMAC method to obtain the total PACs content and is then analyzed by liquid chromatography coupled to mass spectrometry (HPLC-ESI-MS / MS) for the evaluation of the content of A-type Proanthocyanidins (PACs-A) (and the possible presence of PACs-B).

Extractive and analytical techniques

The low temperature extraction technique developed by Biosfered Srl produces an enriched fraction of bioactive PACs-A (from 5% to 20%). MacroPAC-A® thus claims a standardized content of PACs-A. The degree of PACs-A polymerization of MacroPAC-A® is characterized by the presence of a high percentage of dimers and trimers, followed by lower quantities of tetramers, pentamers, hexamers and heptamers, as analyzed by LC-MS and MALDI-qTOF.

A flexible and reliable source of PACs-A for supporting the urinary tract health

Urinary Tract Infections and dosage of PACs

The berries of cranberry are used since hundreds of years as a remedy for diseases of the urinary tract and have attracted attention due to their potential health benefits (Neto, 2007, Mol. Nutr. Food Res. 51:652–664). Studies demonstrated that cranberries are rich in polyphenols, which show potent antioxidant activity (Zheng e Wang, 2003, J. Agric.Food Chem. 51:502–5093), prevent the adhesion of bacteria to host cells in the urinary tract infections (UTI) due to uropathogenic Escherichia coli (Howell, 2007, Mol. Nutr. Food Res. 51:732–737), prevent the formation of gastric ulcers (Burger et al., 2000, FEMS Immunol. Med. Microbiol. 29:295–3015) and fight influenza virus (Luganini A. et al., 2018, Front. Microbiol., 9: 1826) and Herpes virus (Terlizzi et al., 2016, Antiviral Res., 132: 154-164). Moreover, they show protection against oxidation of lipoproteins (Chu e Liu, 2005, Life Sci. 77:1892–190) and reduce in vivo cholesterol (Reed et al., 2001, FASEB J. 15:LB54). Guidelines on urinary tract infections of the European Association of Urology already include products made from cranberry among prophylactic methods of alternative UTI support in women.
In humans, a standardized cranberry powder administration in PACs-A (DMAC) at doses containing 72 mg PAC-A per day, divided in two doses of 36 mg (one in the morning and the other in the evening), provides protection against bacterial adhesion and virulence in the urinary tract (Occipinti et al., 2016, Urology Journal, 13: 2640-2649).
MacroPAC-A® contains variable percentages of PACs-A from 5% to 20% and is a flexible and reliable source of PACs-A for any type of galenic and nutraceutical preparation.

FormulationS

MacroPAC-A® is available in the following formats:

Cranberry extract with 5% PACs-A. 720 grams of product are needed to obtain 36 mg of PACs-A.

 

Cranberry extract with 10% PACs-A. 360 grams of product are needed to obtain 36 mg of PACs-A.

 

Cranberry extract with 15% PACs-A. 240 grams of product are needed to obtain 36 mg of PACs-A

 

Cranberry extract with 20% PACs-A. 180 grams of product are needed to obtain 36 mg of PACs-A.